Patent: 9,889,102
✉ Email this page to a colleague
Summary for Patent: 9,889,102
| Title: | Sigma receptor ligands and methods of modulating cellular protein homeostasis using same |
| Abstract: | The present invention includes compounds useful in preventing, treating or ameliorating Sigma-related disorders or diseases. The compounds of the invention may modulate cellular protein homeostasis, which includes: translation initiation, folding, processing, transport, and degradation (including ubiquitin selective autophagy) of proteins. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound, further comprising administering an effective amount of a compound that inhibits the ubiquitin proteasome system (UPS) and/or autophagic survival pathways. |
| Inventor(s): | Kim; Felix J. (Philadelphia, PA), Salvino; Joseph M. (Chester Springs, PA) |
| Assignee: | Drexel University (Philadelphia, PA) |
| Application Number: | 15/176,812 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,889,102
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Pharmacia & Upjohn Company Llc | SOMAVERT | pegvisomant | For Injection | 021106 | 03/25/2003 | ⤷ Try a Trial | 2032-07-19 |
| Pharmacia & Upjohn Company Llc | SOMAVERT | pegvisomant | For Injection | 021106 | 07/31/2014 | ⤷ Try a Trial | 2032-07-19 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
